{
 "generic_name": "Crinecerfont Capsule",
 "slug": "crinecerfont-capsule",
 "brand_names": [],
 "fda_status": [
  "To Be Discontinued"
 ],
 "last_fda_update": "04/28/2026",
 "first_posted": "04/28/2026",
 "synced_at": "2026-10-01T04:04:04.751Z",
 "presentations": [
  {
   "company": "Neurocrine Biosciences, Inc.",
   "package_ndc": "70370-5025-1",
   "presentation": "Crenessity, Capsule, 25 mg (NDC 70370-5025-1)",
   "availability": "Not specified",
   "availability_raw": null,
   "fda_note": "Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1)."
  }
 ],
 "changes": []
}